Search Results
Sep 03, 2026, 11:30 ET Dyson Airsmooth™: The dryer brush designed for healthier hair
snag-free styling.The Dyson Airsmooth™ is available at Dyson Demo stores, Dyson.com, Sephora, Ulta, Nordstrom, Amazon, Best Buy, Target, .Abt, and Nebraska Furniture Mart on September 8th for $249.99 USD.CONTACT:For
More news about: Dyson
Aug 31, 2026, 08:00 ET Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
Aug. 31, 2026 /PRNewswire/ -- Parents looking for an infant formula made with whole milk now have a new option. Abbott (NYSE: ABT) today announced the launch of Similac® 360 Total Care Made With Whole Milk—the first and only commercially sterile, ready-to-feed liquid
More news about: Abbott
Aug 27, 2026, 09:00 ET Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
effectivenessABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device
More news about: Abbott
Aug 25, 2026, 14:49 ET Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
systemsABBOTT PARK, Ill., Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first
More news about: Abbott
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
development of ABT-301. Our research team is fully committed to maximizing the scientific impact of this collaboration and to providing the scientific evidence needed to support indication expansion and future clinical development of ABT-301."About ABT-301 (Imofinostat)ABT-301 is an orally
More news about: AnBogen Therapeutics
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
development of ABT-301. Our research team is fully committed to maximizing the scientific impact of this collaboration and to providing the scientific evidence needed to support indication expansion and future clinical development of ABT-301."About ABT-301 (Imofinostat)ABT-301 is an orally
More news about: AnBogen Therapeutics
Aug 20, 2026, 16:15 ET Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
enterocolitisABBOTT PARK, Ill., Aug. 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the
More news about: Abbott
Aug 17, 2026, 13:45 ET Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
ABBOTT PARK, Ill. and BETHESDA, Md., Aug. 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) announced a multi-year "food is medicine" effort – called the NACHC and Abbott Food
More news about: Abbott
Aug 12, 2026, 09:14 ET Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
ABBOTT PARK, Ill. and ROSEMONT, Ill., Aug. 12, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, and the Big Ten Conference today announced the return of the "We Give Blood" drive, a nationwide competition uniting all
More news about: Abbott
Aug 11, 2026, 09:00 ET Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
changesABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights
More news about: Abbott
Aug 10, 2026, 09:15 ET Abbott Lanza una Campaña en Español con Gabriela Spanic para Fomentar la Detección del Cáncer de Colon con Cologuard Plus®
ABBOTT PARK, Ill., 10 de agosto de 2026 /PRNewswire-HISPANIC PR WIRE/ -- Abbott (NYSE: ABT) lanzó hoy una nueva campaña en español con la participación de la galardonada actriz, modelo, escritora y cantante Gabriela Spanic, para alentar a más
More news about: Abbott
Jul 30, 2026, 09:00 ET Abbott recebe aprovação da ANVISA para uso de dispositivo bioabsorvível inovador em artérias abaixo do joelho
pernasSão Paulo, July 30, 2026 /PRNewswire/ -- A Abbott (NYSE: ABT), líder global em cuidados para a saúde, anuncia a aprovação regulatória da Agência Nacional de Vigilância Sanitária (ANVISA) para o Esprit BTK, Sistema
More news about: Abbott
Jul 16, 2026, 07:30 ET Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
repurchasesABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026. Second-quarter sales increased 13.0 percent on
More news about: Abbott
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
expanded territorial commercialization rights for cenerimod.AbbVie's RINVOQ (upadacitinib)JAK 1 inhibitorUpadacitinib (ABT-494) is a selective inhibitor of Janus kinase 1 (JAK1) that is approved for the treatment of several immune-mediated inflammatory diseases, including
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 07:36 ET DMEGC Solar presenta sus innovaciones en Intersolar Europe 2026
alta densidad.Segmento residencial:G12RT-G48HBB totalmente negro (hasta 485 W) con tecnología ABT, además de una versión Extreme con resistencia al granizo HW5. Soluciones C&I:G12RT-B54HBT
More news about: DMEGC Solar
Jul 01, 2026, 02:03 ET DMEGC Solar präsentiert auf der Intersolar Europe 2026 Innovationen aus den Bereichen Photovoltaik und Energiespeicherung
fortschrittliche Hochdichte-VerpackungstechnologieWohnimmobiliensegment:Komplett schwarzes G12RT-G48HBB (bis zu 485 W) mit ABT-Technologie sowie ein in der Extreme-Version mit HW5-HagelschutzC&I-Lösungen:G12RT-B54HBT mit einer Leistung von
More news about: DMEGC Solar
Jul 01, 2026, 01:18 ET DMEGC Solar présente ses innovations en matière de photovoltaïque et de stockage d'énergie au salon Intersolar Europe 2026
d'encapsulation à haute densitéSegment résidentiel:G12RT-G48HBB entièrement noir (jusqu'à 485 W) doté de la technologie ABT, ainsi qu'un modèle Extreme avec protection contre la grêle HW5Solutions C&I:Le G12RT-B54HBT, offrant jusqu'à 530
More news about: DMEGC Solar
Jun 30, 2026, 22:41 ET DMEGC Solar Showcases PV and Energy Storage Innovations at Intersolar Europe 2026
driven by advanced high-density encapsulation technologyResidential segment:All-black G12RT-G48HBB (up to 485W) with ABT technology, plus an Extreme version with HW5 hail resistanceC&I solutions:G12RT-B54HBT delivering up to 530W
More news about: DMEGC Solar
Jun 25, 2026, 09:00 ET Abbott hosts conference call for second-quarter earnings
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens. The announcement will be followed by a live webcast
More news about: Abbott
Jun 24, 2026, 08:30 ET ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic
More news about: ALZpath, Inc.
Jun 22, 2026, 12:00 ET New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
TikTok.About Abbott:Abbott (NYSE: ABT) is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum
More news about: Abbott
Jun 12, 2026, 14:29 ET Abbott declares 410th consecutive quarterly dividend
ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410th consecutive quarterly dividend to be paid by
More news about: Abbott
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.
More news about: AbbVie
Jun 11, 2026, 09:00 ET Abbott recebe aprovação para dois novos biossimilares no Brasil, ampliando o acesso ao tratamento da osteoporose e de complicações ósseas relacionadas ao câncer
câncerSÃO PAULO, 11 de junho, 2026 /PRNewswire/ -- A Abbott (NYSE: ABT), líder global em cuidados para a saúde, acaba de receber a aprovação regulatória da Anvisa (Agência Nacional de Vigilância Sanitária) para dois novos
More news about: Abbott